RecruitingPhase 1Phase 2NCT05379985
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Sponsor
Revolution Medicines, Inc.
Enrollment
754 participants
Start Date
May 31, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is testing a new drug called RMC-6236, which targets cancer cells with specific RAS gene mutations — the most commonly mutated cancer gene, found in many tumor types including pancreatic and lung cancers.
**You may be eligible if...**
- You have an advanced solid tumor confirmed to carry a specific KRAS G12 mutation (dose escalation phase) or any RAS mutation (expansion phase)
- You are in good overall health (ECOG performance status 0 or 1)
- You have tried standard treatments for your cancer type, or your cancer has no available standard therapy
- Your organ function is adequate
**You may NOT be eligible if...**
- You have a primary brain tumor
- You have active, untreated brain metastases
- You have a condition that would prevent you from swallowing or absorbing an oral medication
- You have other significant unstable medical conditions
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGRMC-6236
Oral Tablets
Locations(21)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05379985
Related Trials
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
NCT066944541 location
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT042224132 locations
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
NCT0585336725 locations
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
NCT0754057211 locations
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
NCT076217183 locations